<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254448</url>
  </required_header>
  <id_info>
    <org_study_id>TC-5619-238-CLP-003</org_study_id>
    <nct_id>NCT01254448</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease</brief_title>
  <official_title>Two-Part, Sequential Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TC-5619-238 in Elderly Subjects With and Without Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targacept Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targacept Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to examine the safety, tolerability and pharmacokinetics of TC-5619
      in elderly subjects with and without Alzheimer's disease. Group 1 includes elderly subjects
      with Alzheimer's disease to receive TC-5619 or placebo for 28 days to evaluate safety and
      tolerability. Group 2 includes healthy elderly subjects in a dose escalation design to
      receive TC-5619 or placebo for 10 days to evaluate safety, tolerability and pharmacokinetics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Group 1: screening, Days -14, Day -1, Days 1, 2, 3, 27-33; Group 2: Day -14, Day -1, Days 1 -14</time_frame>
    <description>Number of participants with treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profiles</measure>
    <time_frame>Group 1: Days 1, 2, 28-32; Group 2: Day 1, 2, 4, 8, 10-14</time_frame>
    <description>Plasma concentrations (pharmacokinetic profiles) of TC-5619-238 over time (Groups 1 &amp; 2) and urine (Group 2) samples after multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation in cerebrospinal fluid</measure>
    <time_frame>Group 1: Days 1, 2, 28-32; Group 2: Day 1, 2, 4, 8, 10-14</time_frame>
    <description>Changes in markers of inflammation in cerebrospinal fluid (Group 1 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation in plasma</measure>
    <time_frame>Group 1: Days 1, 2, 28-32; Group 2: Day 1, 2, 4, 8, 10-14</time_frame>
    <description>Dose related changes in markers of inflammation in plasma over time (Groups 1 &amp; 2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a placebo capsule orally once a day for 28 days (Group 1) or 10 days (Group 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TC-5619</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a TC-5619 orally once a day for 28 days (Group 1) or 10 days (Group 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5619</intervention_name>
    <description>Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.</description>
    <arm_group_label>TC-5619</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Groups 1 &amp; 2):

          -  Normal body mass index (BMI)

          -  Non-smoking for a minimum of 3 months

          -  Subjects must be in reasonably good health, based on medical history, physical
             examination, vital signs, and ECG.

        Group 1 Only:

          -  Subjects a Mini Mental State Examination score between 12-22, inclusive.

          -  Diagnosis of probable Alzheimer's Disease according to National Institute of
             Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related
             Disorders Association (NINCDS-ADRDA) criteria

          -  Subjects must have a reliable caregiver.

        Exclusion Criteria (Groups 1 &amp; 2):

          -  Subjects with clinically significant heart disease, pulmonary disease, diabetes,
             neurologic or psychiatric disease (Group 1 subjects must have Alzheimer's Disease), or
             any other illness that could interfere with interpretation of study results.

          -  Subjects with a past or current history of seizures cannot participate.

          -  Current use of donepezil, rivastigmine or galantamine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Gerson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Phase One</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Phase One</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>333025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center For Clinical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institutes</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

